Edition:
India

Spring Bank Pharmaceuticals Inc (SBPH.OQ)

SBPH.OQ on NASDAQ Stock Exchange Capital Market

15.62USD
11:05pm IST
Change (% chg)

$-0.37 (-2.31%)
Prev Close
$15.99
Open
$16.06
Day's High
$16.14
Day's Low
$15.61
Volume
2,029
Avg. Vol
9,381
52-wk High
$18.93
52-wk Low
$6.40

Latest Key Developments (Source: Significant Developments)

Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial
Thursday, 16 Nov 2017 

Nov 15 (Reuters) - Spring Bank Pharmaceuticals Inc :Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial.Spring Bank Pharmaceuticals - ‍Inarigivir 50mg daily for 12 weeks met both primary endpoints of safety and efficacy in second cohort of achieve trial​.Spring Bank Pharmaceuticals - ‍inarigivir demonstrated a statistically significant reduction in hbv dna at week 12 compared to combined placebo group​.Spring Bank Pharma - sees Gilead initiating Phase 2 trial examining co-administration of inarigivir, vemlidy​ for infections with chronic HBV in Q1 2018.  Full Article

Spring Bank Pharmaceuticals - Q3 loss per share $0.85
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Spring Bank Pharmaceuticals Inc :Spring Bank Pharmaceuticals provides corporate update and reports third quarter 2017 financial and operational results.Q3 loss per share $0.85.Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S.Spring Bank Pharmaceuticals - top-line results from second inarigivir monotherapy dosing cohort of achieve trial will be released in Q4 2017​.Spring Bank Pharmaceuticals - expects existing cash, cash equivalents, marketable securities will enable co to fund expenses, capex through 2019-end.Spring Bank - expects cash, cash equivalents, marketable securities will not be enough to fund development of inarigivir beyond Phase 2 achieve trial​.  Full Article

Spring Bank Pharmaceuticals Q4 loss per share $0.28
Wednesday, 15 Feb 2017 

Spring Bank Pharmaceuticals Inc : Spring Bank Pharmaceuticals provides corporate update and reports 2016 financial and operational results .Q4 loss per share $0.28.  Full Article

Spring Bank Pharmaceuticals Q2 loss per share $0.62
Tuesday, 2 Aug 2016 

Spring Bank Pharmaceuticals Inc : Q2 loss per share $0.62 .Spring bank pharmaceuticals announces second quarter 2016 financial results and recent highlights.  Full Article

BRIEF-Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial

* Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial